FDA Brief

Warning letters Drugs

FDA warning letter to

Prodrome Sciences USA, LLC

High riskIssued Jan 8Posted Jan 20Center for Drug Evaluation and Research (CDER)

Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

What happened

FDA inspected Prodrome Sciences from December 17, 2024, to January 10, 2025, under its Bioresearch Monitoring Program, which checks how research is run and whether human subjects are protected. The investigator reviewed the company's role as sponsor of Protocol Pro-040-Plasm-01, a study of ProdromeNeuro Oil in people with age-related cognitive decline. FDA found the company started the study without an IND in effect, and 29 subjects were enrolled and received the product between July 2020 and March 2021.

What FDA found

  1. The company began and ran a human study of an unapproved drug without first submitting an IND, the application FDA must allow before an unapproved drug is tested in people.

    21 CFR 312.20(a), 312.20(b), and 312.40(a)
  2. The company called the product a dietary supplement, but the protocol enrolled people with mild to moderate dementia and measured cognitive outcomes, so the product was being studied as a drug.

    Section 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)]
  3. The company's corrective plan did not explain how it will decide whether IND rules apply to future studies.

    21 CFR 312.2(a)

What FDA wants

Within 15 business days of receiving the letter, notify FDA in writing of the actions taken to prevent similar violations. The response must explain in enough detail how the company will decide whether IND rules apply to future studies and what procedures it will follow if an IND is required.

Who should pay attention

  • sponsors running small clinical studies of dietary supplements
  • contract research organizations and clinical investigators enrolling subjects
  • supplement companies making claims about treating disease

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk